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Abstract
Background: With the advent of antiretroviral therapy (ART) cases of immune reconstitution inflammatory syndrome
(IRIS) have increasingly been reported. IRIS usually occurs in individuals with a rapidly rising CD4 T-cell count or
percentage upon initiation of ART, who develop a deregulated immune response to infection with or without reactivation
of opportunistic organisms. Here, we evaluated rises in absolute CD4 T-cells, and specific CD4 T-cell responses in 4
HIV-1+ individuals presenting with mycobacterial associated IRIS who received in conjunction with ART, IL-2 plus GM-
CSF immunotherapy.
Methods: We assessed CD4 T-cell counts, HIV-1 RNA loads, phenotype for naïve and activation markers, and in vitro
proliferative responses. Results were compared with those observed in 11 matched, successfully treated asymptomatic
clinical progressors (CP) with no evidence of opportunistic infections, and uninfected controls.
Results: Median CD4 T-cell counts in IRIS patients rose from 22 cells/µl before initiation of ART, to 70 cells/µl after 8
months of therapy (median 6.5 fold increase). This coincided with IRIS diagnosis, lower levels of naïve CD4 T-cells,
increased expression of immune activation markers, and weak CD4 T-cell responses. In contrast, CP had a median CD4
T-cell counts of 76 cells/µl at baseline, which rose to 249 cells/µl 6 months post ART, when strong T-cell responses were
seen in > 80% of patients. Higher levels of expression of immune activation markers were seen in IRIS patients compared
to CP and UC (IRIS > CP > UC). Immunotherapy with IL-2 and GM-CSF paralleled clinical recovery.
Conclusion: These data suggest that mycobacterial IRIS is associated with inadequate immune reconstitution rather
than vigorous specific T-cell responses, and concomitant administration of IL-2 and GM-CSF immunotherapy with
effective ART may correct/augment T-cell immunity in such setting resulting in clinical benefit.
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Background
The degree of immune reconstitution observed in HIV-1+
individuals following initiation of antiretroviral therapy
(ART), is variable [1-4]. Although seen even in late-stage
disease, it is more prominent in patients who commence
treatment during early HIV-1 infection before substantial
damage to the immune system, where robust responses
are often seen after treatment [5-7]. Such responses likely
reflect effective immune surveillance, mimicking the ben-
eficial T-cell responses seen in untreated long-term non-
progressors, HIV-1 exposed but seronegative individuals,
and after therapeutic vaccination of asymptomatic
patients [8-10].
It has been postulated that after treatment of late-stage
HIV-1 infection, recovery and augmentation of immune
function, and responses to previous sub-clinical infec-
tions with existing pathogens such as Mycobacterium spp,
hepatitis B and hepatitis C viruses, or cytomegalovirus
(CMV) may result in exacerbated inflammatory diseases
[11-19]. This phenomenon, described by others as
immune reconstitution inflammatory syndrome (IRIS), is
mostly seen in profoundly immunosuppressed patients
with CD4 T-cell nadirs of less than 100 cells/µl, who upon
receiving ART rapidly achieve an undetectable plasma
viremia, and experience a very rapid increase in CD4 T
cells [12,14]. This complex syndrome presents with either
active opportunistic infections, or recurrence of previous
infections.
We investigated the quality and breadth of lymphoprolif-
erative responses in a group of HIV-1+ patients on stable
ART for > 6 months with suppressed viremia, diagnosed
with  Mycobacterium avium complex (MAC) associated
IRIS, who were unresponsive to conventional anti-MAC
therapy. We showed that these patients lacked pathogen-
specific in vitro T-cell responses suggesting that the degree
and quality of immune reconstitution following ART is
inadequate to eliminate underlying opportunistic infec-
tions. Furthermore, immunotherapy with IL-2 and GM-
CSF in combination with effective ART appears to acceler-
ate augmentation of specific CD4 T-cell responses and
increase the rapidity of immune recovery allowing under-
lying opportunistic infections to be cleared and leading to
a better immediate outcome and resolution of IRIS.
Methods
Subjects studied
Fifteen HIV-1+ patients at the Chelsea and Westminster
Hospital, London, UK were studied. Four presented with
MAC-associated IRIS, and where acid-fast bacilli were
detected, patients were given anti-MAC therapy as soon as
diagnosed. These patients had a median CD4 T-cell count
of 22 cells/µl (interquartile range (IQR) 6.3–50.3) before
initiation of ART, rising to 70 cells/µl (IQR 63–123) after
8 months of therapy (Table 1). For clarity these subjects
will be referred to as IRIS patients. Previous reports define
IRIS as a syndrome occurring in individuals with a rising
CD4 T-cell count or percentage upon initiation of ART,
who develop new clinical pathologies with either a new
clinical presentation or reactivation of opportunistic
organisms [15,16]. Viral load was undetectable in all
patients at presentation of IRIS. IRIS patients (n = 4)
received immunotherapy as salvage therapy consisting of
IL-2 (Chiron Therapeutics, Uxbridge, UK) at 5 million
units twice daily subcutaneously for 5 days, in three cycles
4 weeks apart. During the third cycle of IL-2, concomitant
GM-CSF (Novartis, Schering-Plough, Camberley, UK) was
administered subcutaneously 150 µg daily for 5 days. The
remaining patients were asymptomatic clinical progres-
sors (n = 11) receiving ART for 6 months, with a median
CD4+ T-cell count of 76 cells/µl (IQR 22.5–90) at base-
line, rising to 249 cells/µl (IQR 187.5–303.5) 6 months
post ART, and with viral load levels from undetectable
(80% of patients) to 127 HIV-1 RNA copies/ml plasma.
These patients developed no secondary effects following
treatment, and had no evidence of opportunistic infec-
tions/exacerbated immune responses. Sixteen healthy
HIV uninfected donors were used as controls. Informed
consent was obtained from all patients for the administra-
tion of immunotherapy and investigations carried out,
and ethics committee approval was obtained for the stud-
ies described.
Plasma viral RNA assay
Viral load was measured at each time point of sample col-
lection using the Bayer HIV-1 RNA 3.0 assay (bDNA)
(Bayer Diagnostics, Newbury, UK) with lower detection
limit of 50 HIV-1 RNA copies/ml plasma.
Lymphocyte subset quantification
The Epics XL-MCL (Beckman Coulter, High Wycombe,
UK) was used for four-colour flow cytometric analysis.
Anti-human CD3, CD4, CD8, and CD45 were used to
analyze T cell subsets. Leukocytes were analysed on the
Epics XL-MCL flow cytometer using system II software in
conjunction with control reagents (Beckman Coulter)
which provide automated colour compensation, light
scatter and colour intensities.
T cell proliferation assay
Peripheral blood mononuclear cells (PBMC) were cul-
tured in triplicate with HIV-1 or other recall/viral antigen
in round-bottomed microtiter plates (Greiner, Gloucester,
UK) for 5 days as described previously [20-22]. The anti-
gens used were: Herpes simplex virus (HSV), purified
avian protein derivative of tuberculin (PPD), tetanus tox-
oid (TTox), Varicella-Zoster virus (VZV), Candida (CAN),
and Cytomegalovirus (CMV) as described in reference 21.
HIV-1 recombinant antigens were obtained from theJournal of Immune Based Therapies and Vaccines 2005, 3:7 http://www.jibtherapies.com/content/3/1/7
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Medical Research Council Centralised Facility for AIDS
Reagents (National Institute for Biological Standards and
Controls, Potters Bar, UK) and comprised: recombinant
HIV-1-nef, recombinant HIV-1-gp120 and recombinant
HIV-1-p24 (all used at 10 µg/ml final concentration) [22].
Adjuvant-free Remune and its native-p24 antigens were a
generous gift from Dr Ronald Moss (Immune Response
Corporation, Carlsbad, USA) and were used at 3 µg/ml to
ensure that anti-HIV-1 responses were not overlooked due
to clade variability. On day 5, 100 µl of supernatant was
collected from each well and stored at -20°C for subse-
quent cytokine measurement, cells were pulsed with
[3H]thymidine (Amersham International, Amersham,
UK) and 16 h later cells were harvested onto glass fiber fil-
termats and counted (Wallac Oy, Turku, Finland). Results
are expressed as stimulation indices (SI) with a positive
response defined as an SI of 3 or more and ∆ counts per
minute (CPM) > 600 as described previously [21-23].
Control wells, for calculation of background activity, con-
tained PBMC only.
Measurement of IL-4 production
Fifty  µl of supernatant from proliferative cultures was
transferred to 96-well round-bottomed plates in triplicate
for quantification of IL-4 on the indicator cell line CT.h4S
(a generous gift of W. Paul, Bethesda, MD) as previously
described [20-22]. Briefly, CT.h4S (5 × 103 cells/well),
were added in 50 µl to 50 µl of supernatant to give a final
volume of 100 µl. After 24 h in culture, wells were pulsed
with [methyl-3H]thymidine, and cells were harvested as
described above. Results are expressed as the mean cpm
for triplicate cultures, with an error of the mean of ± 15%.
A positive result is defined as significant proliferation
above the background activity and detection threshold. In
all experiments, a standard titration of indicator cell pro-
liferation to a range of recombinant IL-4 from 0.01 to 100
U/ml was included. Control wells for calculation of back-
ground activity contained indicator cells only.
Phenotypic analysis of lymphocytes
PMBC were incubated with a panel of murine anti-human
mAbs (all Beckman Coulter), for 30 minutes at 4°C.
Directly conjugated antibodies used were: Fluorescein iso-
thiocyanate (FITC)-CD8, CD45RA; Phycoerytherin (PE)-
CD38, HLA-DR, CD27, and CD45RA; PE-cyanine (PC-5)-
CD4, all used according to the manufacturer's instruc-
tions. Cells were washed and fixed in PBS containing 2%
paraformaldehyde (Sigma). On acquisition, a gate was set
around the lymphocyte population on a forward scatter
versus side scatter dot plot, and 10,000 gated events col-
lected for each sample. Data analysis was performed using
CELLQuest™ Software (Becton Dickinson, Oxford, UK).
Appropriate isotype matched controls were run in parallel
for each sample.
Statistical analysis
Computer software (Statview 5.01; Abacus, Berkeley, CA)
was used for all statistical calculations. Data are presented
as median (inter-quartile range IQR). Analysis of data
between the different groups was performed using a Mann
Whitney-U-test and intra-group variations were compared
using the Wilcoxon signed rank test. P values below 0.05
were considered significant.
Results
Patients
We studied both IRIS and CP patients who had been
receiving effective ART for similar periods. IRIS was diag-
nosed at a median 10 months (IQR 8–13) after initiation
of ART (Table 1). This is in agreement with previous
Table 1: Clinical features of IRIS patients
Patient CD4 T cell 
count before 
ART cells/µl
CD4 T cell 
count at 
presentation 
of IRIS cells/µl
Fold change in 
CD4 T cell 
counts from 
baseline to 
IRIS 
presentation
CD4 T cell 
count after 
remission of 
IRIS cells/µl
HIV-1 RNA at 
presentation of 
IRIS copies/ml
Reason for 
admission
Time on 
therapy*
Therapy
1 7 69 9.86 202 U/D MAC 8 d4T+ddI+NF
V+ImRx
2 37 70 1.89 140 U/D MAC 12 AZT+3TC+I
DV+ImRx
3 4 45 11.25 93 U/D MAC 18 d4T+ddI+NF
V+ImRx
4 90 280 3.11 601 U/D MAC 8 AZT+3TC+E
FV+ImRx
*Time in months from initiation of potent ART until diagnosis of IRIS. Drugs used in ART regime: Nucleoside analogues; Stavudine (d4T), 
Didanosine (ddI), Lamivudine (3TC) and Zidovudine (AZT) Protease inhibitors; Nelfinavir (NFV), Indinavir (IDV), or Non-nucleoside reverse 
transcriptase inhibitor; Efavirenz (EFV); ImRx = immunotherapy; MAC = Mycobacterium avium complex.Journal of Immune Based Therapies and Vaccines 2005, 3:7 http://www.jibtherapies.com/content/3/1/7
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reports [24]. The patients did not recover from the under-
lying MAC infection despite receiving conventional anti-
MAC treatment, and were given IL-2 and GM-CSF in con-
junction with ART as salvage therapy as detailed in mate-
rials and methods and as previously described [9,21].
Increases in CD4 T-cell counts from baseline to IRIS diag-
nosis were observed in all patients. Viral load reached BDL
in all patients and remained undetectable throughout the
study.
IRIS patients receiving ART plus immunotherapy
Immunotherapy was initiated for severely immuno-com-
promised patients with exacerbated underlying MAC
infection (IRIS) who were unable to achieve remission
after receiving ART and anti-mycobacterial therapy. Four
patients with median CD4+ T-cell counts of 70 cells/µl
(IQR 63–123) after a median 10 months on ART, with
persistent MAC infection, received IL-2 and GM-CSF (see
Table 1 for drug regimen). PPD-specific T-cell responses
and responses to other recall/viral antigens were absent in
all patients before immunotherapy (Fig 1a). After admin-
istration of immunotherapy, we saw an increase in
median CD4+ T-cell counts to 171 cells/µl (IQR 128–302)
(Table 1). Moreover, we observed robust antigen-specific
T-cell responses to a panel of antigens including PPD.
Such responses were sometimes more vigorous than those
observed in patients on ART alone (Fig 1a), and were par-
alleled by remission from the underlying MAC infection.
Furthermore, immune reconstitution characterised by a
rise in CD4 T-cell counts and constant undetectable
plasma viremia was achieved. Patient 4 was admitted with
localised MAC associated lymphadenitis of the neck and
lacked in vitro proliferative responses to PPD and other
recall antigens despite a CD4 T-cell count of 280 cells/l
µblood. After administration of immunotherapy we
observed a rapid recovery in immune function (Fig 2a).
The parallel clinical manifestations depicted an improve-
ment in the neck lesion after IL-2 therapy and complete
remission post administration of IL-2 plus GM-CSF (Fig
2b–d). We also observed an increase in CD4 T-cell counts
from 280 to 601 cells/µl during this period (Table 1). No
significant changes were seen in HIV-1-specific T-cell
responses, which remained undetectable throughout the
study (Fig 1b).
In 3/4 IRIS patients we carried out IL-4 bioassays in cul-
ture supernatants, rather than ELISA, in order to assess the
levels of bioactive cytokine being produced. We were able
to detect production of IL-4 in cultures with antigens to
which the patients had been previously exposed including
anti-PPD responses in 2/3 patients (Fig 3). Upon initia-
tion of immunotherapy there was a decrease in IL-4 pro-
duction, which was paralleled by restoration of
proliferative specific-anti-PPD T-cell responses.
Lymphoproliferative T-cell responses to recall/viral 
antigens in asymptomatic clinical progressors and 
seronegative controls
We assessed T-cell proliferation in CP and uninfected con-
trols (UC) and compared these with the responses seen in
IRIS patients. CP presented a median 3.9 fold increase in
CD4 T-cell counts 6 months post initiation of ART from
76 cells/µl (IQR 22.5–90) to 249 cells/µl (IQR 187.5–
303.5) (p < 0.001) (Table 1). These patients remained
clinically asymptomatic and had detectable specific T-cell
responses to at least one recall antigen (Fig 4). All UC
showed vigorous responses to recall antigens (Fig 4).
Flow cytometry revealed higher levels of CD38 and HLA-
DR expression and lower levels of naïve CD4 T cells in IRIS 
patients than in asymptomatic clinical progressors
Compared to CP, IRIS patients showed significantly
higher percentages of CD4+HLA-DR+ T lymphocytes (p <
0.005), and significantly higher percentages of
CD8+CD38+ T cells (p < 0.05) (Table 2). When activation
was quantified on a per cell basis, IRIS patients showed
higher levels of activation of both CD4 and CD8 T cells
compared to CP (p < 0.02 and p < 0.01, respectively), as
demonstrated by analysing the mean fluorescent intensity
levels of CD38 expression (Table 2). Furthermore, the
median percentage of naïve CD4+CD45RA+CD27+ T cells
in IRIS patients was significantly lower than in CP and UC
(p < 0.005). These observations are not surprising as IRIS
patients were more immuno-compromised when therapy
was initiated suggesting that IRIS may be associated with
persistent hyperactivation of both CD4 and CD8 T lym-
phocytes, and associated with a lack of naïve CD4 T cells
possibly due to absence of thymic function.
Discussion
Immune reconstitution after initiation of ART may be
concurrent with both an increase in immuno-pathologi-
cal responses against opportunistic pathogens and with
the induction of IRIS [11-19,24]. The IRIS phenomenon
has been ascribed to vigorous immune responses specific
to underlying pathogens, with clinical manifestations
related to the immune response elicited against such path-
ogens. Typically, IRIS patients have an undetectable viral
load, and CD4 T-cell counts that have rapidly increased,
by 3 or 4 fold, shortly after initiation of ART. Previous
studies have used delayed type hypersensitivity (DTH)
tests to assess the cell-mediated immunity of these
patients [12,14,15]. In contrast, we used the thymidine
incorporation assay to evaluate lymphocyte proliferation.
This allows visualisation of in vitro immune function of T
lymphocytes in peripheral blood and direct comparison
with asymptomatic HIV-1+ subjects as well as uninfected
controls. Some reports have shown the lack of correlation
between these two assays [25], as functionally T-cellJournal of Immune Based Therapies and Vaccines 2005, 3:7 http://www.jibtherapies.com/content/3/1/7
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(a – top) Lymphoproliferative responses to a panel of recall antigens in IRIS patients during IRIS manifestation and post  remission Figure 1
(a – top) Lymphoproliferative responses to a panel of recall antigens in IRIS patients during IRIS manifestation 
and post remission. Open bars denote T cell responses during IRIS manifestation and hatched bars represent T cell 
responses after immunotherapy with IL-2 plus GM-CSF in conjunction with ART and resolution of IRIS. Data are shown as 
median SI values with interquartile ranges. X-axis depicts the recall antigens tested. (b- bottom) HIV-1-specific lympho-
proliferative responses in IRIS patients. Data depicted are before immunotherapy (solid bars), 4 weeks after IL-2 admin-
istration (crossed bars) and 4 weeks after IL-2 plus GM-CSF (hatched bars). Data are shown as median values with interquartile 
ranges.
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proliferation and DTH responses can diverge [26]. There-
fore, by utilising the thymidine incorporation assay, we
demonstrate the correlation between in vitro functional
data and clinical evidence.
There were two important findings in this study. Firstly,
patients admitted with IRIS lacked antigen-specific T-cell
responses. Secondly, administration of IL-2 and GM-CSF
appeared to rapidly introduce these responses and was
associated with clinical recovery in patients with advanced
HIV-1 infection.
Data from uninfected controls and treated asymptomatic
clinical progressors, revealed the presence of lymphopro-
liferative responses to recall/viral antigens, compared to
IRIS patients, confirming that functional specific T lym-
phocytes are associated with the control of opportunistic
infections. Thus, the clinical picture presented by our
cohort of IRIS patients is likely to be associated with the
lack of lymphoproliferation and IL-2 production rather
than with robust antigen-specific T cell responses. This
suggests an alternative/additional mechanism for IRIS,
distinct from previous hypotheses which suggest that IRIS
(a – top) Specific lymphoproliferative responses to recall antigens of patient 4 Figure 2
(a – top) Specific lymphoproliferative responses to recall antigens of patient 4. Data are at IRIS presentation (white 
bars), 4 weeks after IL-2 administration (hatched bars) and 4 weeks post final IL-2 and GM-CSF dosing (solid bars). Photo-
graphs depict the clinical manifestation of MAC lymphadenitis of the neck in patient 4, at IRIS presentation (b – bottom left), 
4 weeks after IL-2 administration (c- bottom centre), and 4 weeks after IL-2 plus GM-CSF administration (d – bottom 
right).
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is caused by pathogen-specific responses induced by suc-
cessful ART.
Of note, are the generally weak proliferative responses
observed in response to other pathogens such as CMV,
which recover after initiation of ART [27,28]. Although
complete immune impairment appears to be restricted to
HIV-1 and PPD antigens, other studies have reported
CMV-specific responses to remain generally unchanged in
HIV-1+ patients, regardless of the patients' HIV viral loads
and clinical state [29]. Different reasons may explain this
observation: CMV viraemia is often very low or undetect-
able and thus fails to induce robust T cell responses [29];
in addition CMV does not target the antigen presenting
cells such as dendritic cells and macrophages hence ena-
bling the uninfected antigen presenting cells to efficiently
carry out processing and presentation and to generate spe-
cific T-cell responses – unlike mycobacteria and HIV-1
which are both known to target antigen presenting cells.
In addition, our group has previously shown that in gen-
eral, HSV- and CMV-specific T-cell responses appear to be
more robust in both CP and LTNP [22,28].
The mechanisms behind IRIS still remain elusive.
Through cell-to-cell contact, various complex molecular
interactions and the production of cytokines, CD4 T
helper lymphocytes modulate the activity of all cells
involved in both innate and acquired immunity, includ-
ing virus-specific cytotoxic CD8 T lymphocytes [30-33].
Although anti-HIV-1 CD8 T cells are present in chroni-
cally infected individuals, they lack specific functional
properties, most likely because CD4 T cell help is
impaired [34-37]. The HIV-1-induced defect of CD4 T-cell
responses is likely to be an underlying mechanism causa-
tive of anergy and subsequently IRIS, due to defective anti-
gen presentation and lack of T-cell help.
The use of immunotherapy in severely immuno-compro-
mised patients has been shown to have beneficial effects
in partially reversing the CD4 T-cell defects exerted by
HIV-1, when administered concomitantly with ART
[9,21]. Such data concurs with our previous findings that
concomitant administration of ART and IL-2 plus GM-
CSF reversed the type 2 anti-proliferative cytokine envi-
ronment, decreasing IL-4 levels and inducing pathogen-
specific proliferative responses. We have previously
shown that such regimens induce HIV-1-specific prolifer-
ative CD4 and IFN-γ secreting CD8 T-cells. In these stud-
ies, HIV-1-specific proliferative responses paralleled by
increased IL-2 production, responsiveness and up-regu-
lated expression of IL-2-specific mRNA were associated
with remission of disease [21]. It is important to note that,
in previous studies, GM-CSF was administered at doses
twice the level of those described here, thus possibly
inducing HIV-1-specific immunity. This may explain our
inability to induce detectable HIV-1-specific T-cell
responses despite a decline in IL-4 production. Regardless,
in our cohort of immunotherapy recipients, remission
from MAC occurred rapidly despite profound immuno-
suppression.
IL-4 production in culture supernatants of PBMC from 2 patients Figure 3
IL-4 production in culture supernatants of PBMC from 2 patients. Data are from 5 days stimulation with/without PPD 
and p24 antigens, before immunotherapy (white bars) and 4 weeks after administration of IL-2 plus GM-CSF (hatched bars). 
Data are expressed as the mean cpm (proliferation of cell line CT.h4S) for triplicate cultures, with an error of the mean of ± 
15%.
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During HIV-1 infection immune hyperactivation is
accompanied by up-regulation of surface expression of
CD38 and HLA-DR on CD4 and CD8 T cells [38-41].
Higher T-cell activation in the IRIS cohort compared to CP
is not surprising, as T-cell specific responses were much
lower in IRIS patients. This is in concordance with data
from Caruso et al describing the occasional lack of corre-
lation between the percentage of T cells expressing activa-
tion markers and thymidine incorporation [42]. It is
suggested that hyperactivation by HIV-1 and other under-
lying pathogens is associated with activation induced cell
death and/or anergy [43]. Furthermore, high HLA-DR
levels are suggestive of increased T cell↔T cell antigen
presentation, which is associated with induction of T-cell
anergy/dysfunction and increased IL-4 production
[44,45]. This is in agreement with our previous findings
that anergised antigen-specific T cells are present at base-
line in immunocompromised patients but lack prolifera-
tive/functional ability [21]. The lower levels of naïve T
cells observed in IRIS patients compared to CP may be
due to a more immunocompromised state and possibly
reflect thymic dysfunction/inactivity.
Our data suggests that the degree of immune reconstitu-
tion achieved with potent ART alone is dependent on the
clinical stage of the patient when therapy was initiated.
Furthermore, we hypothesise that in some late-stage
patients ART may elicit the expansion of abnormal/aner-
gic T cell clones responsible for an erratic immune
response. Concomitant administration of IL-2 and GM-
CSF may be associated with provision of proliferative sig-
nals to immature thymocytes and/or rescue of anergic
CD4 T cells to generate fully functional T-cell responses.
GM-CSF acts directly on antigen presenting cells, includ-
ing macrophages, which may induce and contribute to a
more rapid remission from intracellular infection [46-48].
Box-plots depicting specific lymphoproliferative responses to different recall antigens, during manifestation of IRIS and compar- ison with clinical progressors with no IRIS and uninfected controls Figure 4
Box-plots depicting specific lymphoproliferative responses to different recall antigens, during manifestation of 
IRIS and comparison with clinical progressors with no IRIS and uninfected controls. The antigens used are shown 
on the x-axis. Bars denote median responses with interquartile ranges. White boxplots represent IRIS patients receiving ART 
and immunotherapy. Non-IRIS patients are depicted by dotted boxplots and uninfected controls by hatched boxplots.
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Conclusion
In conclusion, ART induced immune reconstitution
restores specific responses, which likely help in the clear-
ance of opportunistic pathogens. However, inadequate
immune responses observed in treated late-stage disease,
in addition to other possible confounders, may be causa-
tive of IRIS. Administration of IL-2 and GM-CSF concom-
itantly with ART in late-stage patients may result in
proliferation of pathogen-specific CD4 T-lymphocytes,
which likely enable a more rapid clearance of intracellular
pathogens such as Mycobacterium avium. Such responses
may be associated with a better outcome and, possibly
quicker recovery, in immuno-compromised patients who
fail to achieve immune reconstitution with ART alone,
indicating that this therapeutic approach as salvage
immuno-therapy may have an impact on short-term mor-
tality. The small number of patients is noteworthy- this is
nonetheless an interesting and provocative finding that
deserves further prospective exploration in larger numbers
of similar patients.
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